Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin

  • G. G. Neznamov
  • E. S. Teleshova


Mild Cognitive Impairment Mini Mental State Examination Daytime Drowsiness Piracetam Mini Mental State Examination Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    A. S. Avedisova, R. V. Akhankin, V. I. Akhapkina, et al., “Analysis of non-Russian studies of nootropic agents (using piracetam as an example), Ros. Psikhiat. Zh., 1, 57–63 (2001).Google Scholar
  2. 2.
    G. Ya. Avrutskii and A. I. Niss, Pharmacology of the Nootropes (Experimental and Clinical Studies) [in Russian], Moscow (1989), pp. 112–118.Google Scholar
  3. 3.
    Yu. A. Aleksandrovskii, G. M. Rudenko, G. G. Neznamov, et al., A Unified System for Evaluating the Clinical-Pharmacological Actions of Psychotropic Agents in Patients with Borderline Neuropsychiatric Disorders [in Russian], Moscow (1984).Google Scholar
  4. 4.
    Yu. A. Aleksandrovskii, Psychopharmacotherapy [in Russian], Moscow (2005).Google Scholar
  5. 5.
    A. V. Valdman and T. A. Voronina, Pharmacology of the Nootropes (Experimental and Clinical Studies). Collected Studies [in Russian], Moscow (1989).Google Scholar
  6. 6.
    T. A. Voronina and S. B. Seredenin, “Nootropic agents, advances and new problems,” Éksperim. Klin. Farmakol., 61, No. 4, 3–9 (1998).Google Scholar
  7. 7.
    S. I. Gavrilova, The Pharmacotherapy of Alzheimer's Disease [in Russian], Puls, Moscow (2003).Google Scholar
  8. 8.
    G. Glants, Medical and Biological Statistics [Russian translation from English], Moscow (1999).Google Scholar
  9. 9.
    T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, et al., “Peptide analogs of piracetam as ligands of presumptive nootrope receptors,” Khim.-Farm. Zh., 11, 1322–1329 (1985).Google Scholar
  10. 10.
    I. V. Lamulin, Mild Cognitive Impairments. Methodological Guidelines for Doctors [in Russian], RKI Severo Press, Moscow (2004).Google Scholar
  11. 11.
    V. V. Zakharov and N. N. Yakhno, Memory Disorders, GEOTARMED, Moscow (2003).Google Scholar
  12. 12.
    Ya. B. Kalyn', Mental Health of the Population of Elderly and Aged People (A Clinical-Epidemiological Study) [in Russian], Author's Abstract of Doctoral Thesis in Medical Sciences, Moscow (2001).Google Scholar
  13. 13.
    G. V. Kovalev, Nootropic Substances [in Russian], Volgograd (1990).Google Scholar
  14. 14.
    O. S. Levin, “Diagnosis and treatment of moderate cognitive impairments in the elderly,” Zh. Nevrol. Psikhiat., 8, 42–49 (2006).Google Scholar
  15. 15.
    International Statistical Classification of Diseases and Health-Related Problems (ICD-10) [Russian translation], WHO, Geneva (1995).Google Scholar
  16. 16.
    S. N. Mosolov, Basic Psychopharmacology [in Russian], Vostok, Moscow (1996).Google Scholar
  17. 17.
    G. G. Neznamov, S. A. Syunyakov, I. A. Davydova, and E. S. Teleshova, “The ‘fast’ and 'slow’ components of the psychotropic actions of agents with nootropic properties,” Zh. Nevrol. Psikhiat., 100, No. 6, 33–37 (2000).Google Scholar
  18. 18.
    G. G. Neznamov, E. S. Teleshova, S. A. Syunyakov, et al., “Treatment of mental disorders in neurology. Clinical studies of the new peptide agent Noopept in patients with psychoorganic disorders,” Consilium Medicum (Neurology/Mental Disorders), 9, No. 2, 10–15 (2007).Google Scholar
  19. 19.
    R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, and S. B. Seredenin, “The original nootropic and neuroprotective dipeptide Noopept (GVS-111),” Éksper. Klin. Farmakol., 65, No. 5, 66–72 (2002).Google Scholar
  20. 20.
    S. A. Piyavskii, Numerical Decision-Taking Methods in Computerized Methods in Technical Creativity in Construction [in Russian], ASV, Moscow (1994).Google Scholar
  21. 21.
    Handbook of Psychiatry [in Russian], A. S. Tiganov (ed.), Meditsina, Moscow (1999), Vol. 2.Google Scholar
  22. 22.
    V. I. Sergienko and I. B. Bondareva, Mathematical Statistics in Clinical Trials [in Russian], Moscow (2001).Google Scholar
  23. 23.
    A. A. Skoromets, Neurotransmitters in Brain Aging: the Key to Understanding Memory and Attention Disorders [in Russian], Moscow (2005).Google Scholar
  24. 24.
    E. Arnaiz and O. Almkvist, “Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease,” Acta Neurol. Scand., 107, Supplement 179, 34–41 (2003).CrossRefGoogle Scholar
  25. 25.
    D. A. Bennett, “Mild cognitive impairment,” Clin. Geriat. Med., 20, 15–25 (2004).CrossRefGoogle Scholar
  26. 26.
    H. Braak, K. Del Tredici, and E. Braak, “Spectrum of pathology,” in: Mild Cognitive Impairment, R. C. Petersen (ed.), Oxford University Press (2003), pp. 149–189.Google Scholar
  27. 27.
    C. E. Coffey, W. E. Wilkinson, I. A. Parashos, et al., “Quantitative cerebral anatomy of the aging human brain,” Neurology, 42, 527–536 (1992).PubMedGoogle Scholar
  28. 28.
    H. C. Comijs, M. G. Dik, D. J. H. Deeg, et al., “The course of cognitive decline in older patients,” Dement. Geriat. Cogn. Dis., 17, 136–142 (2004).CrossRefGoogle Scholar
  29. 29.
    E. Daly, D. Zaitchik, M. Copeland, et al., Clinical Predictors of Conversion to Alzheimer's Disease, B. Vellas et al. (eds.), Serdi Publisher, Paris (2001), Vol. 5, pp. 44–49.Google Scholar
  30. 30.
    W. Danysz, C. G. Parsons, H.-J. Mobius, et al., “Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-A unified glutamatergic hypothesis on the mechanism of action,” Neurotox. Res., 2, 85–97 (2000).PubMedCrossRefGoogle Scholar
  31. 31.
    D. De Wied, Neurochemical and Psychopharmacological Approaches to Cognitive Entracers, Kyoto (1995).Google Scholar
  32. 32.
    M. F. Folstein, S. E. Folstein, and P. R. McHugh, J. Psychiat. Res., 12, No. 3, 189–198 (1975).PubMedCrossRefGoogle Scholar
  33. 33.
    C. Giurgea, “Vers une pharmacologie de l'activite integrative du cerveau. Tentative du concept nootrop en psychopharmacologie,” Actual Pharmacol., 25, 115–157 (1972).Google Scholar
  34. 34.
    T. Gudasheva, T. Voronina, R. Ostrovskaya, et al., “Synthesis and antiamnestic activity of a series of N-acylprolyl-containing dipeptides,” Eur. J. Med. Chem., 31, 151–157 (1996).CrossRefGoogle Scholar
  35. 35.
    J. W. Jacobs, M. R. Bernhard, F. Delgado, and J. J. Strain, Ann. Int. Med., 86, 40–46 (1977).PubMedGoogle Scholar
  36. 36.
    D. S. Knopman, B. F. Boeve, and R. C. Petersen, “Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia,” Mayo Clinic Proc., 78, 1290–1308 (2003).CrossRefGoogle Scholar
  37. 37.
    National Institute of Mental Health, 12-CGI. Clinical Global Impression, W. Guyo (ed.), ECDEU Assessment Manual for Psychopharmacology, Rockville, Maryland (1976), 217–222.Google Scholar
  38. 38.
    R. Ostrovskaya et al., Anxiolytic Activity of Nootropic Dipeptide Noopept, Nova Sci. Publ. (2006), Vol. 10, pp. 1–10.Google Scholar
  39. 39.
    K. Palmer, L. Backman, B. Winblad, and L. Fratiglioni, “Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study,” Brit. Med. J., 326, 245–249 (2003).PubMedCrossRefGoogle Scholar
  40. 40.
    R. S. Petersen, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, 303–308 (1999).PubMedCrossRefGoogle Scholar
  41. 41.
    R. S. Petersen, “Mild cognitive impairment: transition from aging to Alzheimer's disease,” in: Advances of Etiology, Pathogenesis, and Therapeutics, K. Igbal et al. (eds.), Wiley, Chichester, etc. (2001), pp. 140–151.Google Scholar
  42. 42.
    B. Reisberg, S. H. Ferris, et al., Psychopharm. Bull., 19, 47–50 (1983).Google Scholar
  43. 43.
    K. Ritchie, S. Artero, and J. Touchon, “Classification criteria for mild cognitive impairment. A population-based validation study,” Neurology, 56, 37–42 (2001).PubMedGoogle Scholar
  44. 44.
    S. Seredenin, T. Voronina, T. Gudasheva, R. Ostrovskaya, et al., “Biologically active N-acylprolyldipeptides having antiamnestic, antihypoxic, and anorexigenic effects,” US Patent No. 5439930 (1995).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2009

Authors and Affiliations

  • G. G. Neznamov
    • 1
  • E. S. Teleshova
    • 1
  1. 1.Clinical Psychopharmacology Laboratory, V. V. Zakusov State Research Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations